SEARCH

SEARCH BY CITATION

References

  • Abshire, T. & Kenet, G. (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis, 2, 899909.
  • Butenas, S., Brummel, K.E., Paradis, S.G. & Mann, K.G. (2003a) Influence of factor VIIa and phospholipids on coagulation in ‘‘acquired’’ hemophilia. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 123129.
  • Butenas, S., Brummel, K.E., Bouchard, B.A. & Mann, K.G. (2003b) How factor VIIa works in hemophilia. Journal of Thrombosis and Haemostasis, 1, 11581160.
  • Cawthern, K.M., Van't Veer, C.V., Lock, J.B., DiLorenzo, M.E., Branda, R.F. & Mann, K.G. (1998) Blood coagulation in hemophilia A and hemophilia C. Blood, 91, 45814592.
  • Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Gungor, T., Krackhardt, B. & Kornhuber, B. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594598.
  • Fenger-Eriksen, C., Anker-Moller, E., Heslop, J., Ingerslev, J. & Sørensen, B. (2005) Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. British Journal of Anaesthesia, 94, 324329.
  • Hoffman, M. & Monroe, III, D.M. (2001) The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Seminars in Hematology, 38, 69.
  • Hvitfeldt, P.L., Christiansen, K., Sorensen, B. & Ingerslev, J. (2006) Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scandinavian Journal of Clinical and Laboratory Investigation, 66, 329336.
  • Ingerslev, J., Feldstedt, M. & Sindet-Pedersen, S. (1991) Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII. Lancet, 338, 831832.
  • Ingerslev, J., Poulsen, L.H. & Sørensen, B. (2003) Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia, 9, 348352.
  • Kreuz, W., Escuriola-Ettingshausen, C., Martinez-Saguer, I., Kaiml, M. & Kornhuber, B. (1999) Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates. Vox Sanguinis, 77(Suppl. 1), 38.
  • Lisman, T., De Groot, P.G., Lambert, T., Rojkjaer, R. & Persson, E. (2003) Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. Journal of Thrombosis and Haemostasis, 1, 21752178.
  • Ljung, R., Petrini, P., Lindgren, A.C., Tengborn, L. & Nilsson, I.M. (1992) Factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 1550.
  • Martinowitz, U., Livnat, T., Zivelin, A., Luboshitz, J., Seligsohn, U. & Kenet, G. (2005) Concomitant infusion of low doses of rFVIIa and FEIBA in severe haemophilia A patients with an inhibitor to factor VIII who are refractory to rFVIIa or FEIBA has an excellent haemostatic effect and synergistically enhances thrombin generation. Journal of Thrombosis and Haemostasis, 3, P0637 (Abstract).
  • Persson, E. & Olsen, O.H. (2002) Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes. European Journal of Biochemistry, 269, 59505955.
  • Persson, E., Bak, H. & Olsen, O.H. (2001a) Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity. Journal of Biological Chemistry, 276, 2919529199.
  • Persson, E., Kjalke, M. & Olsen, O.H. (2001b) Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proceedings of the National Academy of Sciences of the United States of America, 98, 1358313588.
  • Persson, E., Bak, H., Ostergaard, A. & Olsen, O.H. (2004) Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement. Biochemical Journal, 379, 497503.
  • Polgar, J., Matuskova, J. & Wagner, D.D. (2005) The P-selectin, tissue factor, coagulation triad. Journal of Thrombosis and Haemostasis, 3, 15901596.
  • Rand, M.D., Lock, J.B., Van't Veer, C., Gaffney, D.P. & Mann, K.G. (1996) Blood clotting in minimally altered whole blood. Blood, 88, 34323445.
  • Rivard, G.E., Brummel-Ziedins, K.E., Mann, K.G., Fan, L., Hofer, A. & Cohen, E. (2005) Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. Journal of Thrombosis and Haemostasis, 3, 20392043.
  • Scharrer, I., Bray, G.L. & Neutzling, O. (1999) Incidence of inhibitors in haemophilia A patients–a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia, 5, 145154.
  • Schneiderman, J., Nugent, D.J. & Young, G. (2004) Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia, 10, 347351.
  • Sørensen, B. & Ingerslev, J. (2003) Potential effect of recombinant factor VIIa in ex vivo reversal of pentasaccharide induced anticoagulation. Journal of Thrombosis and Haemostasis, 1, P1108 (Abstract).
  • Sørensen, B. & Ingerslev, J. (2004a) Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. Journal of Thrombosis and Haemostasis, 2, 102110.
  • Sørensen, B. & Ingerslev, J. (2004b) Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Seminars in Hematology, 41(Suppl. 1), 140144.
  • Sørensen, B. & Ingerslev, J. (2005) Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thrombelastography. Haemophilia, 11(Suppl. 1), 16.
  • Sørensen, B., Johansen, P., Christiansen, K., Wöelke, M. & Ingerslev, J. (2003a) Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. Journal of Thrombosis and Haemostasis, 1, 551558.
  • Sørensen, B., Johansen, P., Nielsen, G.L., Sorensen, J.C. & Ingerslev, J. (2003b) Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagulation and Fibrinolysis, 14, 469477.
  • Sørensen, B., Fenger-Eriksen, C. & Ingerslev, J. (2005a) Recombinant factor VIIa fails to correct coagulopathy induced by haemodilution with colloid. British Journal of Anaesthesia, 94, 862863.
  • Sørensen, B., Johansen, P., Christiansen, K., Norengaard, L., Larsen, O.H., Hvas, A.M. & Ingerslev, J. (2005b) What the standard APTT didn't tell you – dynamic plasma clotting parameters reveal hypercoagulation. Blood, 106, 739740 ( Abstract no. 2634).
  • Tranholm, M., Kristensen, K., Kristensen, A.T., Pyke, C., Rojkjaer, R. & Persson, E. (2003) Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood, 102, 36153620.
  • Tripodi, A., Chantarangkul, V., Martinelli, I., Bucciarelli, P. & Mannucci, P.M. (2004) A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood, 104, 36313634.
  • Wight, J. & Paisley, S. (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia, 9, 418435.